BioMarin Pharmaceutical (BMRN) reported Wednesday that its trial for Palynziq in adolescents with phenylketonuria showed a significant reduction in blood phenylalanine levels in patients aged 12 to 17.
The study met its primary efficacy endpoint, demonstrating that Palynziq was more effective than diet alone in lowering blood Phe levels. The safety results were consistent with the known profile of the medicine.
The company plans to present detailed findings at an upcoming medical meeting and will seek regulatory approval later this year to expand Palynziq's label for adolescent use.
Price: 68.00, Change: +0.06, Percent Change: +0.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。